134 related articles for article (PubMed ID: 20961754)
1. 3D-QSAR, homology modeling, and molecular docking studies on spiropiperidines analogues as agonists of nociceptin/orphanin FQ receptor.
Liu M; He L; Hu X; Liu P; Luo HB
Bioorg Med Chem Lett; 2010 Dec; 20(23):7004-10. PubMed ID: 20961754
[TBL] [Abstract][Full Text] [Related]
2. Structural requirements of N-substituted spiropiperidine analogues as agonists of nociceptin/orphanin FQ receptor.
Bao P; Zhang X; Ren H; Li Y; Mu Z; Zhang S; Li G; Yang L
Int J Mol Sci; 2011; 12(12):8961-81. PubMed ID: 22272114
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists.
Meyer ME; Doshi A; Yasuda D; Zaveri NT
AAPS J; 2021 May; 23(3):68. PubMed ID: 33974173
[TBL] [Abstract][Full Text] [Related]
4. Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation.
Daga PR; Zaveri NT
Proteins; 2012 Aug; 80(8):1948-61. PubMed ID: 22489047
[TBL] [Abstract][Full Text] [Related]
5. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands.
Caldwell JP; Matasi JJ; Zhang H; Fawzi A; Tulshian DB
Bioorg Med Chem Lett; 2007 Apr; 17(8):2281-4. PubMed ID: 17289383
[TBL] [Abstract][Full Text] [Related]
7. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands: part 2.
Caldwell JP; Matasi JJ; Fernandez X; McLeod RL; Zhang H; Fawzi A; Tulshian DB
Bioorg Med Chem Lett; 2009 Feb; 19(4):1164-7. PubMed ID: 19147350
[TBL] [Abstract][Full Text] [Related]
9. "In silico" study of the binding of two novel antagonists to the nociceptin receptor.
Della Longa S; Arcovito A
J Comput Aided Mol Des; 2018 Feb; 32(2):385-400. PubMed ID: 29340866
[TBL] [Abstract][Full Text] [Related]
10. Discovery of N-(2-hydroxy-2-aryl-cyclohexyl) substituted spiropiperidines as GlyT1 antagonists with improved pharmacological profile.
Ceccarelli SM; Pinard E; Stalder H; Alberati D
Bioorg Med Chem Lett; 2006 Jan; 16(2):354-7. PubMed ID: 16246561
[TBL] [Abstract][Full Text] [Related]
11. Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-activity relationships for (4-arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives.
Hayashi S; Ohashi K; Mihara S; Nakata E; Emoto C; Ohta A
Eur J Med Chem; 2016 May; 114():345-64. PubMed ID: 27043173
[TBL] [Abstract][Full Text] [Related]
12. Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification.
Daga PR; Polgar WE; Zaveri NT
J Chem Inf Model; 2014 Oct; 54(10):2732-43. PubMed ID: 25148595
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.
Lin AP; Ko MC
ACS Chem Neurosci; 2013 Feb; 4(2):214-24. PubMed ID: 23421672
[TBL] [Abstract][Full Text] [Related]
14. Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.
Jian Y; He Y; Yang J; Han W; Zhai X; Zhao Y; Li Y
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29473866
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide.
Trapella C; Fischetti C; Pela' M; Lazzari I; Guerrini R; Calo' G; Rizzi A; Camarda V; Lambert DG; McDonald J; Regoli D; Salvadori S
Bioorg Med Chem; 2009 Jul; 17(14):5080-95. PubMed ID: 19527931
[TBL] [Abstract][Full Text] [Related]
16. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Structure-Activity Relationships of Triazaspirodecanone Derivatives as Nociceptin/Orphanin FQ Receptor Ligands.
Corrado S; Battisti UM; Sorbi C; Tait A; Malfacini D; Camarda V; Calò G; Brasili L
Chem Biol Drug Des; 2015 Oct; 86(4):447-58. PubMed ID: 25546401
[TBL] [Abstract][Full Text] [Related]
18. Mechanical hyperalgesia in rats with diabetic polyneuropathy is selectively inhibited by local peripheral nociceptin/orphanin FQ receptor and µ-opioid receptor agonism.
Schiene K; Tzschentke TM; Schröder W; Christoph T
Eur J Pharmacol; 2015 May; 754():61-5. PubMed ID: 25697471
[TBL] [Abstract][Full Text] [Related]
19. The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.
Zaveri NT
Curr Top Med Chem; 2011; 11(9):1151-6. PubMed ID: 21050175
[TBL] [Abstract][Full Text] [Related]
20. Nociceptin/orphanin FQ receptors modulate the discriminative stimulus effects of oxycodone in C57BL/6 mice.
Walentiny DM; Wiebelhaus JM; Beardsley PM
Drug Alcohol Depend; 2018 Jun; 187():335-342. PubMed ID: 29705547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
